An experimental treatment strategy for metastatic pancreatic cancer may help patients live longer by making tumors more visible to the immune system, according to a study published in Nature Medicine. OU Health Stephenson Cancer Center enrolled patients on the clinical trial, which studied a new drug called quemliclustat.